Loading company
$15.73-2.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 30, 2026
Past performance
- 1W
- -4.4%
- 1M
- -5.3%
- 3M
- +1.7%
- 6M
- -0.7%
- 1Y
- +2.5%
- 5Y
- -45.6%
$15.73-2.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 30, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $83.7M | $73.5M | +13.93% |
| Profit | $31.7M | $31.6M | +0.48% |
| Profit per share | $0.23 | $0.23 | 0.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aurinia Pharmaceuticals Inc.’s Item 2.02 8-K filed October 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Aurinia Pharmaceuticals Inc. has no earnings call transcript available.
Just reported
From Aurinia Pharmaceuticals Inc.'s results release of October 30, 2026; its quarterly report has since been filed.
Actual
$83.7M
+14% y/y
+0.6% q/q
Guided
—
No guide given
Actual
$0.23
0.0% y/y
-18% q/q
Guided
—
No guide given
Actual
$35.4M
+19% y/y
-24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.